登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05861271,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
The pathology of early breast cancer after surgery is T1micN0: histologically confirmed that the longest diameter of invasive cancer does not exceed 1mm or the maximum diameter of multiple invasive lesions is less than 1mm, and the lymph node is negative (N0);
入选标准第 2 条
The pathological type of immunohistochemistry needs to meet the following conditions: HER-2 (3+) or HER-2 (0-2+) but amplified by FISH detection.
入选标准第 3 条
ECOG score≦ 1 point;
入选标准第 6 条
Blood routine: ANC ≥1.5×109/L, PLT≥100×109/L, blood Hb≥ 9 g/dl (no transfusion within 14 days);
入选标准第 8 条
Liver function: total bilirubin ≤1.25×ULN; AST and ALT <2.5×ULN;
入选标准第 9 条
Renal function: creatinine clearance ≥ 50 mL/min, blood creatinine ≤ 1.5 ×ULN;
入选标准第 10 条
Pregnant or lactating women, women of childbearing age who cannot be effectively contraceptives;
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗;影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05861271,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Women aged 18-70; The pathology of early breast cancer after surgery is T1micN0: histologically confirmed that the longest diameter of invasive cancer does not exceed 1mm or the maximum diameter of multiple invasive lesions is less than 1mm, and the lymph node is negative (N0); The pathological type of immunohistochemistry needs to meet the following conditions: HER-2 (3+) or HER-2 (0-2+) but amplified by FISH detection. Hormone receptor negative (HR-) is defined as ER, PR expression is <1%; Hormone receptor positivity (HR+) is defined as ER and/or PR expression ≥1%. For patients with both invasive lesions, if both lesions are HER-2 positive, they can be enrolled. ECOG score≦ 1 point; No obvious dysfunction of major organs; Blood routine: ANC ≥1.5×109/L, PLT≥100×109/L, blood Hb≥ 9 g/dl (no transfusion within 14 days); Liver function: total bilirubin ≤1.25×ULN; AST and ALT <2.5×ULN; Renal function: creatinine clearance ≥ 50 mL/min, blood creatinine ≤ 1.5 ×ULN; Cardiac function: ECG is generally normal, QTc< 470 ms; LVEF > 50%; contraception during treatment for women of childbearing age; No history of other malignant tumors in the past 5 years; With the consent of the person and signed the informed consent form, or signed by the patient's legal representative with the authorization of the patient. Can be followed up and good compliance.排除标准:Exclusion Criteria:
The maximum size of the infiltrate is more than 1mm in diameter or the axillary lymph node is positive HER2 negative: immunohistochemical HER2-,+; Immunohistochemical HER2+ while FISH has no amplification; Patients who have received neoadjuvant therapy or any other form of systemic therapy or local therapy other than surgery, including chemotherapy, targeted, radiotherapy, or endocrine therapy, prior to enrollment History of other malignant tumors, except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; Metastasis of any part; Pregnant or lactating women, women of childbearing age who cannot be effectively contraceptives; Patients who participate in other clinical trials at the same time; Severe organ function (heart, lung, liver and kidney) insufficiency, LEVF < 50% (ultracardiogram); severe cardiovascular and cerebrovascular diseases (such as: unstable angina, chronic heart failure, uncontrollable hypertension >150/90mmgh, myocardial infarction or cerebrovascular accident) within 6 months before enrollment; diabetics with poor glycemic control; Patients with severe hypertension; Severe or uncontrolled infection; Those who have a history of psychotropic substance abuse and cannot quit or have a history of mental disorders; Patients who are judged by the investigator to be unsuitable to participate in this study.
引自 ClinicalTrials.gov, NCT05861271, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05861271,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。